Novo Nordisk boosts Prothena on plans for amyloidosis therapy
Source: SeekingAlpha
2025-08-06 10:03:06 ET
More on Novo Nordisk, Prothena
- GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
- Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
- Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
- Novo Nordisk plans cost cuts amid slower Wegovy growth outlook
- Novo Nordisk GAAP EPADR of DKK 12.49, revenue of DKK 154.94B; updates FY outlook
Read the full article on Seeking Alpha
For further details see:
Novo Nordisk boosts Prothena on plans for amyloidosis therapy
Prothena Corporation plc
NASDAQ: PRTA
PRTA Trading
-4.37% G/L:
$9.64 Last:
242,431 Volume:
$9.70 Open:
PRTA Latest News
March 09, 2026 04:05:00 pm
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy
PRTA Stock Data
$486,084,737
38,757,587
1.22%
55
N/A
Biotechnology & Life Sciences
Healthcare
IE
Dublin 2
